— Know what they know.
Not Investment Advice

RXST NASDAQ

RxSight, Inc.
1W: +12.8% 1M: -14.2% 3M: -26.4% YTD: -38.8% 1Y: -61.8% 3Y: -73.0%
$6.08
-0.27 (-4.17%)
 
Weekly Expected Move ±9.6%
$5 $5 $6 $6 $7
NASDAQ · Healthcare · Medical - Devices · Alpha Radar Sell · Power 30 · $251.9M mcap · 39M float · 1.89% daily turnover · Short 32% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$251.9M
52W Range5.3-16.48
Volume393,136
Avg Volume734,131
Beta1.24
Dividend
Analyst Ratings
3 Buy 7 Hold 2 Sell
Consensus Hold
Company Info
CEORonald Kurtz
Employees498
SectorHealthcare
IndustryMedical - Devices
IPO Date2021-07-30
100 Columbia
Aliso Viejo, CA 92656
US
949 521 7830
About RxSight, Inc.

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Recent Insider Trades

NameTypeSharesPriceDate
Goldshleger Ilya M-Exempt 12,489 $4.13 2026-04-17
Goldshleger Ilya M-Exempt 12,489 $4.13 2026-04-17
Wilterding Mark M-Exempt 20,441 2026-02-28
Wilterding Mark M-Exempt 20,441 2026-02-28
Wilterding Mark F-InKind 8,068 $7.61 2026-02-28

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms